Allergy Therapeutics targets accelerating Grassmuno sales as peanut vaccine advances to next trial phase

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU), the immunotherapy company, expects commercial momentum to build through the second half of its financial year as its newly launched Grassmuno grass pollen treatment gains traction in Germany, while planning advances for a phase IIb trial of its short-course peanut allergy vaccine candidate. Grassmuno, an injected grass pollen allergen immunotherapy that received German regulatory approval during the period, launched in January 2026 and has seen a strong early response from prescribing clinicians, with the company describing it as an expected major driver of revenue in its largest market.